or Try an Advanced Search...

    Technical Analysis for IXHL - Incannex Healthcare Limited

    Grade Last Price % Change Price Change
    D 2.95 0.34% 0.01
    IXHL closed up 0.34 percent on Monday, July 1, 2024, on 20 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Flat Up Down
    Historical IXHL trend table...
    Date Alert Name Type % Chg
    200 DMA Resistance Bearish 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    BB Squeeze Started Range Contraction 0.00%
    Gapped Up Strength 0.00%
    200 DMA Resistance Bearish 0.34%
    Crossed Above 50 DMA Bullish 0.34%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.34%
    BB Squeeze Ended Range Expansion 0.34%
    Older End-of-Day Signals for IXHL ...

       Recent Intraday Alerts

    Alert Time
    200 DMA Support about 9 hours ago
    Non-ADX 1,2,3,4 Pullback Entry about 9 hours ago
    Rose Above Previous Day's High about 9 hours ago
    Rose Above 200 DMA about 9 hours ago
    Up 2% about 9 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    IXHL Chart by TradingView
    Basic chart:

    Profile

    Incannex Healthcare Limited Description

    Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.

    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Drugs Organ Systems Neuroscience Chemical Compounds Rheumatoid Arthritis Asthma Inflammatory Bowel Disease Respiratory Therapy Chronic Obstructive Pulmonary Disease Sleep Apnea Sleep Disorders Obstructive Sleep Apnea Cannabidiol Cannabinoid Acute Respiratory Distress Syndrome Traumatic Brain Injury

    Is IXHL a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 30 Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
    May 7 Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder
    Apr 16 Incannex Healthcare Inc. Quarterly Update, Q1 2024
    Feb 28 Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Feb 28 Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder
    Feb 16 Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation
    Feb 1 Clarion Clinics Open for Psychedelic-Assisted Treatments
    Jan 27 Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
    Jan 24 Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis
    Jan 12 Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
    See more IXHL news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 12.68
    52 Week Low 0.8
    Average Volume 28,007
    200-Day Moving Average 2.96
    50-Day Moving Average 2.84
    20-Day Moving Average 3.20
    10-Day Moving Average 3.22
    Average True Range 0.26
    RSI (14) 45.95
    ADX 21.64
    +DI 12.37
    -DI 24.35
    Chandelier Exit (Long, 3 ATRs) 2.76
    Chandelier Exit (Short, 3 ATRs) 3.45
    Upper Bollinger Bands 3.63
    Lower Bollinger Band 2.77
    Percent B (%b) 0.21
    BandWidth 26.96
    MACD Line 0.03
    MACD Signal Line 0.10
    MACD Histogram -0.0709
    Fundamentals Value
    Market Cap 46.82 Million
    Num Shares 15.9 Million
    EPS -0.88
    Price-to-Earnings (P/E) Ratio -3.35
    Price-to-Sales 49.46
    Price-to-Book 0.88
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.10
    Resistance 3 (R3) 3.11 3.06 3.08
    Resistance 2 (R2) 3.06 3.03 3.06 3.07
    Resistance 1 (R1) 3.01 3.00 2.99 3.00 3.06
    Pivot Point 2.96 2.96 2.95 2.96 2.96
    Support 1 (S1) 2.91 2.93 2.89 2.90 2.84
    Support 2 (S2) 2.86 2.90 2.86 2.83
    Support 3 (S3) 2.81 2.86 2.83
    Support 4 (S4) 2.80